Drugs / SIM1803-1A
SIM1803-1A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04671849 | Dec 2020 → Sep 2022 | NTRK fusion positive cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIM1803-1A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04671849 ↗ |
| Action | Inhibit | “SIM1803-1A is a drug that blocks the actions of these NTRK/ ROS1 /ALK genes in cancer cells” NCT04671849 ↗ |
| Target | ALK | “The cancer must have a change in a particular gene (NTRK1, NTRK2, NTRK3, ROS1 or ALK). SIM1803-1A is a drug that blocks the actions of these NTRK/ ROS1 /ALK genes in cancer...” NCT04671849 ↗ |
| Target | NTRK1 | “The cancer must have a change in a particular gene (NTRK1, NTRK2, NTRK3, ROS1 or ALK). SIM1803-1A is a drug that blocks the actions of these NTRK/ ROS1 /ALK genes in cancer...” NCT04671849 ↗ |
| Target | NTRK2 | “The cancer must have a change in a particular gene (NTRK1, NTRK2, NTRK3, ROS1 or ALK). SIM1803-1A is a drug that blocks the actions of these NTRK/ ROS1 /ALK genes in cancer...” NCT04671849 ↗ |
| Target | NTRK3 | “The cancer must have a change in a particular gene (NTRK1, NTRK2, NTRK3, ROS1 or ALK). SIM1803-1A is a drug that blocks the actions of these NTRK/ ROS1 /ALK genes in cancer...” NCT04671849 ↗ |
| Target | ROS1 | “The cancer must have a change in a particular gene (NTRK1, NTRK2, NTRK3, ROS1 or ALK). SIM1803-1A is a drug that blocks the actions of these NTRK/ ROS1 /ALK genes in cancer...” NCT04671849 ↗ |